Equities Analysts Offer Predictions for Alkermes Q1 Earnings

Key Points

• Zacks Research has raised its Q1 2026 earnings estimates for Alkermes from $0.39 to $0.44 per share, while the full-year earnings consensus is currently at $1.31 per share.
• Alkermes' stock has received various ratings, with one analyst giving a "Strong Buy," eight "Buy," and three "Hold" ratings, along with an average price target of $41.08.
• In recent insider trading, SVP Christian Todd Nichols sold 3,334 shares, decreasing his ownership to 86,208 shares valued at approximately $2.68 million.

Alkermes plc (NASDAQ:ALKS - Free Report) - Equities researchers at Zacks Research increased their Q1 2026 earnings estimates for Alkermes in a research report issued to clients and investors on Tuesday, August 19th. Zacks Research analyst Team now forecasts that the company will post earnings of $0.44 per share for the quarter, up from their prior forecast of $0.39. The consensus estimate for Alkermes' current full-year earnings is $1.31 per share. Zacks Research also issued estimates for Alkermes' Q1 2027 earnings at $0.33 EPS.

Other equities research analysts have also recently issued research reports about the stock. Needham & Company LLC restated a "buy" rating and set a $45.00 target price on shares of Alkermes in a research note on Tuesday, July 29th. Robert W. Baird upped their price target on shares of Alkermes from $38.00 to $41.00 and gave the stock an "outperform" rating in a research report on Friday, May 2nd. Cantor Fitzgerald upgraded shares of Alkermes to a "strong-buy" rating in a research report on Tuesday, May 13th. HC Wainwright reiterated a "neutral" rating and issued a $46.00 price target on shares of Alkermes in a research report on Monday, July 21st. Finally, The Goldman Sachs Group began coverage on shares of Alkermes in a research report on Tuesday, July 15th. They issued a "buy" rating and a $43.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $41.08.

Alkermes Price Performance

Shares of ALKS traded down $0.75 on Thursday, reaching $29.00. The company's stock had a trading volume of 1,082,514 shares, compared to its average volume of 1,753,421. The stock has a market capitalization of $4.79 billion, a P/E ratio of 13.94, a PEG ratio of 1.71 and a beta of 0.47. The stock's 50 day simple moving average is $28.34 and its two-hundred day simple moving average is $30.45. Alkermes has a 12-month low of $25.56 and a 12-month high of $36.45.

Alkermes (NASDAQ:ALKS - Get Free Report) last announced its quarterly earnings results on Tuesday, July 29th. The company reported $0.52 EPS for the quarter, topping analysts' consensus estimates of $0.42 by $0.10. The firm had revenue of $390.66 million during the quarter, compared to analyst estimates of $343.20 million. Alkermes had a net margin of 23.15% and a return on equity of 24.86%. The business's revenue for the quarter was down 2.1% on a year-over-year basis. During the same period in the previous year, the business posted $1.16 earnings per share. Alkermes has set its FY 2025 guidance at 1.030-1.210 EPS.

Insider Transactions at Alkermes

In other Alkermes news, SVP Christian Todd Nichols sold 3,334 shares of the stock in a transaction that occurred on Tuesday, June 10th. The shares were sold at an average price of $31.09, for a total transaction of $103,654.06. Following the completion of the sale, the senior vice president directly owned 86,208 shares of the company's stock, valued at $2,680,206.72. This trade represents a 3.72% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 4.40% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Twin Tree Management LP purchased a new stake in Alkermes during the first quarter valued at $29,000. Armstrong Advisory Group Inc. purchased a new stake in Alkermes during the second quarter valued at $29,000. Brooklyn Investment Group raised its stake in Alkermes by 1,071.1% during the first quarter. Brooklyn Investment Group now owns 1,054 shares of the company's stock valued at $35,000 after purchasing an additional 964 shares in the last quarter. Quantbot Technologies LP raised its stake in Alkermes by 54.5% during the first quarter. Quantbot Technologies LP now owns 1,091 shares of the company's stock valued at $36,000 after purchasing an additional 385 shares in the last quarter. Finally, USA Financial Formulas purchased a new stake in Alkermes during the first quarter valued at $49,000. 95.21% of the stock is currently owned by institutional investors.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.